Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.50 |
| ▸ | PARP11 | Q9NR21 | 11/20 | 0.50 |
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24681313 | 0.82 | PARP10 (0.60) | ACHEPARP10PARP11PARP1F7 | |
| SCHEMBL14992245 | 0.82 | ACHE (0.51) | NOTUMACHEPARP10PARP11PARP1 | |
| SCHEMBL11450232 | 0.81 | CDK5 (0.47) | NOTUMACHEHTR2AHTR2CHTR2B | |
| SCHEMBL30233773 | 0.78 | PARP1 (0.64) | ACHEPARP10PARP11PARP1HTT | |
| SCHEMBL797996 | 0.78 | PARP1 (0.64) | ACHEPARP10PARP11PARP1HTT | |
| SCHEMBL15814364 | 0.77 | HTT (0.51) | NOTUMACHEPARP10PARP11PARP1 | |
| SCHEMBL30402278 | 0.74 | ACHE (0.50) | NOTUMACHEPARP10PARP11PARP1 | |
| SCHEMBL10129821 | 0.74 | ACHE (0.50) | NOTUMACHEPARP10PARP11PARP1 | |
| SCHEMBL31749685 | 0.73 | PARP10 (0.54) | ACHEPARP10PARP11PARP1HTT | |
| SCHEMBL8526899 | 0.72 | NOTUM (1.00) | NOTUMHTTPTK2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499121-B1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | HOFFMANN LA ROCHE (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-9133158-B2 | Bicyclic dihydroisoquinoline-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8354441-B2 | Oxazoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143863-A1 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | NOTUM 1375/4885ACHE 4312/4885PARP10 2931/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | NOTUM 3760/4885ACHE 616/4885PARP10 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.